Popular Trials
Monoclonal Antibodies
RBS-001 vs Eylea for Age-Related Macular Degeneration
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial aims to show that two different treatments, RBS-001 and Eylea, are equally effective and safe in treating a specific eye condition called Neovascular age-related macular degeneration
Anti-VEGF Therapy
Axitinib Implant for Age-Related Macular Degeneration
Recruiting2 awardsPhase 3
Santa Barbara, California
This trial is testing a small device placed in the eye that releases medication for patients with a severe form of AMD. The medication helps stop abnormal blood vessel growth in the eye, potentially preventing further vision loss. This approach has significantly improved treatment for this condition in recent years.
Popular Filters
Trials for Macular Degeneration Patients
Gene Therapy
Gene Therapy (ADVM-022) for Age-Related Macular Degeneration
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing a gene therapy product, ADVM-022, for the treatment of neovascular or wet age-related macular degeneration (nAMD). The product is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.
Monoclonal Antibodies
SUSVIMO for Age-Related Macular Degeneration
Recruiting3 awardsPhase 4
Mesa, Arizona
This trial will assess the response to treatment with SUSVIMO given every 24 weeks in patients with nAMD who have been previously treated with anti-VEGF agents. A substudy will evaluate the impact of SUSVIMO on corneal endothelial cells.
Vascular Endothelial Growth Factor (VEGF) Inhibitor
OPT-302 + Aflibercept for Age-Related Macular Degeneration
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial will compare a new treatment to a sham (fake) treatment in order to see if the new treatment is effective. The primary efficacy will be determined at Week 52, meaning that's how long the trial will last.
Gene Therapy
RGX-314 Gene Therapy for Wet Age-Related Macular Degeneration
Recruiting1 awardPhase 2 & 3
Phoenix, Arizona
This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. It aims to help the eye make its own medicine to stop harmful blood vessels from causing vision loss. This could reduce the need for regular injections. RGX-314 modifies the retina's cells to create a treatment that may only be needed once.
Gene Therapy
RGX-314 Gene Therapy for Age-Related Macular Degeneration
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is evaluating a potential new treatment for a disease that causes vision loss. The current standard of care for this disease requires life-long, repeated injections to maintain efficacy, but this new treatment would only require a single injection.
Trials for Age-Related Macular Degeneration Patients
Complement Inhibitor
Iptacopan for Age-Related Macular Degeneration
Recruiting0 awardsPhase 2
Coral Springs, Florida
This trial tests if Iptacopan capsules can prevent worsening of early or intermediate AMD in people who already have severe AMD in one eye. The goal is to see if the medication can protect eye cells and slow down vision loss.
Gene Therapy
RGX-314 Gene Therapy for Wet Age-Related Macular Degeneration
Recruiting1 awardPhase 2 & 3
Phoenix, Arizona
This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. It aims to help the eye make its own medicine to stop harmful blood vessels from causing vision loss. This could reduce the need for regular injections. RGX-314 modifies the retina's cells to create a treatment that may only be needed once.
Gene Therapy
RGX-314 for Age-Related Macular Degeneration
Recruiting1 awardPhase 2
Santa Barbara, California
This trial will evaluate the safety & efficacy of RGX-314 over 5yrs in people who have received it in one eye in a previous study. A substudy will look at its safety & immunogenicity in the fellow eye.
Anti-VEGF
Aflibercept for Age-Related Macular Degeneration and Diabetic Macular Edema
Recruiting2 awardsPhase 3
Waterford, Connecticut
This trial is testing a new drug called aflibercept 8 mg on people with nAMD and DME who have already used other medications. The goal is to see how safe and effective the drug
Phase 3 Trials
Vascular Endothelial Growth Factor (VEGF) Inhibitor
OPT-302 + Aflibercept for Age-Related Macular Degeneration
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial will compare a new treatment to a sham (fake) treatment in order to see if the new treatment is effective. The primary efficacy will be determined at Week 52, meaning that's how long the trial will last.
Gene Therapy
RGX-314 Gene Therapy for Wet Age-Related Macular Degeneration
Recruiting1 awardPhase 2 & 3
Phoenix, Arizona
This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. It aims to help the eye make its own medicine to stop harmful blood vessels from causing vision loss. This could reduce the need for regular injections. RGX-314 modifies the retina's cells to create a treatment that may only be needed once.
Anti-VEGF
Aflibercept for Age-Related Macular Degeneration and Diabetic Macular Edema
Recruiting2 awardsPhase 3
Waterford, Connecticut
This trial is testing a new drug called aflibercept 8 mg on people with nAMD and DME who have already used other medications. The goal is to see how safe and effective the drug
Trials With No Placebo
Gene Therapy
Gene Therapy (ADVM-022) for Age-Related Macular Degeneration
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing a gene therapy product, ADVM-022, for the treatment of neovascular or wet age-related macular degeneration (nAMD). The product is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.
Monoclonal Antibodies
SUSVIMO for Age-Related Macular Degeneration
Recruiting3 awardsPhase 4
Mesa, Arizona
This trial will assess the response to treatment with SUSVIMO given every 24 weeks in patients with nAMD who have been previously treated with anti-VEGF agents. A substudy will evaluate the impact of SUSVIMO on corneal endothelial cells.
Gene Therapy
RGX-314 Gene Therapy for Wet Age-Related Macular Degeneration
Recruiting1 awardPhase 2 & 3
Phoenix, Arizona
This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. It aims to help the eye make its own medicine to stop harmful blood vessels from causing vision loss. This could reduce the need for regular injections. RGX-314 modifies the retina's cells to create a treatment that may only be needed once.
Gene Therapy
RGX-314 Gene Therapy for Age-Related Macular Degeneration
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is evaluating a potential new treatment for a disease that causes vision loss. The current standard of care for this disease requires life-long, repeated injections to maintain efficacy, but this new treatment would only require a single injection.
Gene Therapy
RGX-314 for Age-Related Macular Degeneration
Recruiting1 awardPhase 2
Santa Barbara, California
This trial will evaluate the safety & efficacy of RGX-314 over 5yrs in people who have received it in one eye in a previous study. A substudy will look at its safety & immunogenicity in the fellow eye.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.